A cancer marker and treatment in one? Researchers finds promise in non-human sialic acid antibodies
April 19, 2011 in CancerResearchers at the University of California, San Diego School of Medicine say antibodies to a non-human sugar molecule commonly found in people may be useful as a future biomarker for predicting cancer risk, for diagnosing cancer cases early and, in sufficient concentration, used as a treatment for suppressing tumor growth.
The work was led by Richard Schwab, MD, assistant clinical professor of medicine, and Ajit Varki, MD, professor of medicine and cellular and molecular medicine, with other faculty at the UCSD Moores Cancer Center and the UCSD Glycobiology Research and Training Center. Collaborators include researchers from the groups of Xi Chen at UC Davis, Inder Verma at the Salk Institute and scientists from Sialix, Inc., a biotechnology company based in Vista, CA.
It is published in the April 19 online issue of the journal Cancer Research and in the May 1 print edition.
Every animal cell is cloaked in complex molecules called sialic acids that serve as vital contact points for interaction with other cells and the surrounding environment. Humans produce a particular kind of sialic acid called N-acetylneuraminic acid (Neu5Ac), but can also carry another non-human type called N-glycolylneuraminic acid or Neu5Gc, which is obtained through the diet, notably by the consumption of red meat. The molecular structures of these sialic acids differ by just a single oxygen atom, but this difference is enough to prompt the human immune system to produce a complex anti-Neu5Gc response.
In previous research, Varki and colleagues described how low-dose anti-Neu5Gc antibodies can lead to chronic inflammation, an immunological response associated with cancer development and growth. In the new work, using a novel sialoglycan-microarray, the team discovered that patients with carcinomas have elevated levels of antibodies to one specific Neu5Gc-containing sugar chain. This unusual antigen arises from dietary Neu5Gc incorporation into the cancer marker Sialyl-Tn. It is the first example of a biomarker in the form of human "xeno-autoantibodies" to a dietary molecule.
Following up on this discovery, the scientists also found that purified human anti-Neu5Gc antibodies have immunotherapeutic potential: they specifically kill Neu5Gc-expressing mouse or human tumors when applied at higher concentrations. These findings point to a dual response of anti-Neu5Gc antibodies that can either stimulate tumor growth at a low dose (serving as a biomarker of disease) or suppress tumor growth at a high dose.
"Precisely how therapeutic antibodies work in patients remains unclear, even in therapies already approved by the Food and Drug Administration," said Schwab. "It is likely a combination of signaling immune cells to kill cancer cells and antibodies directly killing cells by recruiting other proteins in the body. Understanding how lower levels of antibodies stimulate cancer growth while strong responses can kill cancer cells will be critical to moving this approach safely into cancer treatment."
Schwab noted that many questions and much research remains to be done. Long-term studies are required to learn whether levels of anti-Neu5Gc antibodies are a reliable indicator of future cancer risk, if this risk can be reduced, and if they can be used for early detection of cancers. Developing these antibodies as cancer treatments will require further study of how exactly the antibodies act against Neu5Gc-expressing tumors.
Nonetheless, Schwab expressed optimism about the significance and future of the work.
"This is the first evidence that anti-Neu5Gc antibodies may be useful for the early detection of cancer, identifying cancer risk, or for treatment," he said. "The biggest problem with advancing this work is that sugars are inherently difficult to study, but more people are beginning to pay attention including the National Cancer Institute, which organized a specific multi-institute glycomics program that funded our project. A blood test that could detect cancer early or identify a modifiable risk for cancer would be a tremendous breakthrough in cancer care."
Provided by University of California - San Diego (news : web)
-
Non-human sugar in biotech drugs causes inflammation
Jul 25, 2010 |
not rated yet |
0
-
Missing molecule raises diabetes risk in humans
Mar 02, 2011 |
not rated yet |
0
-
Gene therapy protocol activates immune system in patients with leukemia
Feb 11, 2008 |
not rated yet |
0
-
Antibodies Against Abnormal Glycoproteins Identified as Possible Biomarkers for Cancer Detection
Feb 02, 2010 |
not rated yet |
0
-
New way to kill cancer found using body's immune system
Jul 21, 2009 |
not rated yet |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (3) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
Your brain on 'shrooms: fMRI elucidates neural correlates of psilocybin psychedelic state
Feb 29, 2012 |
4.9 / 5 (41) |
45
-
Your brain on dye: Imaging neuronal voltage with fluorescent sensors and molecular wires
Feb 24, 2012 |
4.9 / 5 (9) |
0
-
Understanding the mechanisms of disease .
May 14, 2012
-
Short burst of hypersensitivity disorder?
May 13, 2012
-
Copper aspirinate
May 12, 2012
-
Ultraviolet rays and diseases
May 12, 2012
-
Article: Robot Reveals the Inner Workings of Brain Cells
May 11, 2012
-
Recommend to me the textbook on an inflammation, please
May 08, 2012
- More from Physics Forums - Medical Sciences
More news stories
Hormone-depleting drug shows promise against localized high-risk prostate tumors
A hormone-depleting drug approved last year for the treatment of metastatic prostate cancer can help eliminate or nearly eliminate tumors in many patients with aggressive cancers that have yet to spread beyond the prostate, ...
Cancer
4 hours ago |
5 / 5 (1) |
0
Experimental agent may help older people with chronic leukemia
The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial.
Cancer
4 hours ago |
not rated yet |
0
Phase I study of temsirolimus, capecitabine proves safe; positive survival trend seen
A phase I clinical trial examining the safety of combining temsirolimus and capecitabine in advanced malignancies suggests the two agents can be given safely to patients. In addition, the Georgetown Lombardi Comprehensive ...
Cancer
4 hours ago |
5 / 5 (1) |
0
Revised glioblastoma classification should improve patient care
Radiation oncology researchers have revised the system used by doctors since the 1990s to determine the prognosis of people with glioblastoma, which is the most devastating of malignant brain tumors.
Cancer
4 hours ago |
not rated yet |
0
Study combines lapatinib with cetuximab to overcome resistance in EGFR-driven tumors
Targeted therapies have been studied for years, but recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy. ...
Cancer
4 hours ago |
not rated yet |
0
Paralyzed individuals control robotic arms to reach and grasp using brain computer interface (w/ Video)
In an ongoing clinical trial, a paralyzed woman was able to reach for and sip from a drink on her own for the first time in nearly 15 years by using her thoughts to direct a robotic arm. The ...
Zebrafish study isolates gene related to autism, schizophrenia and obesity
What can a fish tell us about human brain development? Researchers at Duke University Medical Center transplanted a set of human genes into a zebrafish and then used it to identify genes responsible for head ...
ApoE4 Alzheimer's gene causes brain's blood vessels to leak, die
Common variants of the ApoE gene are strongly associated with the risk of developing late-onset Alzheimer's disease, but the gene's role in the disease has been unclear. Now, researchers funded by the National ...
Landscape of cancer genes and mutational processes in breast cancer
In a study published today in Nature, researchers describe nine new genes that drive the development of breast cancer. This takes the tally of all genes associated with breast cancer development to 40.
Experts say psychiatry's diagnostic manual needs overhaul
The Diagnostic and Statistical Manual of Mental Disorders (DSM), long the master reference work in psychiatry, is seriously flawed and needs radical change from its current "field guide" form, according to an essay by two ...
Study finds common antibiotic azithromycin carries heart risk
Vanderbilt researchers have discovered a rare, but important risk posed by the antibiotic azithromycin, commonly called a "Z-pack." The study found a 2.5-fold higher risk of death from cardiovascular death in the first five ...